Juno Therapeutics Inc (NASDAQ:JUNO) shares gapped down before the market opened on Friday following insider selling activity. The stock had previously closed at $72.90, but opened at $71.37. Juno Therapeutics shares last traded at $67.81, with a volume of 5223347 shares changing hands.
Specifically, CEO Hans Edgar Bishop sold 270,250 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the transaction, the chief executive officer now directly owns 2,772,679 shares of the company’s stock, valued at $128,014,589.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Robert Azelby sold 1,816 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the transaction, the executive vice president now directly owns 70,832 shares in the company, valued at $3,184,606.72. The disclosure for this sale can be found here. Insiders sold 365,337 shares of company stock worth $17,540,499 over the last ninety days. Insiders own 15.08% of the company’s stock.
A number of research analysts have weighed in on the stock. Citigroup lowered shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday. Raymond James Financial reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Wednesday. Cowen reiterated a “buy” rating on shares of Juno Therapeutics in a report on Friday, November 3rd. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, Wells Fargo & Co downgraded shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 12th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $47.26.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter last year, the company posted ($0.57) earnings per share. The firm’s quarterly revenue was up 115.4% compared to the same quarter last year. research analysts anticipate that Juno Therapeutics Inc will post -4.02 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new stake in Juno Therapeutics during the fourth quarter worth about $173,000. CAPROCK Group Inc. purchased a new stake in Juno Therapeutics during the fourth quarter worth about $260,000. Schwab Charles Investment Management Inc. increased its holdings in Juno Therapeutics by 16.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 378,195 shares of the biopharmaceutical company’s stock worth $17,288,000 after buying an additional 53,821 shares during the last quarter. California Public Employees Retirement System increased its holdings in Juno Therapeutics by 2.7% during the third quarter. California Public Employees Retirement System now owns 73,100 shares of the biopharmaceutical company’s stock worth $3,279,000 after buying an additional 1,900 shares during the last quarter. Finally, Capital Bank & Trust Co purchased a new stake in Juno Therapeutics during the third quarter worth about $8,517,000. Institutional investors and hedge funds own 69.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Juno Therapeutics (JUNO) Shares Gap Down on Insider Selling” was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3146722/juno-therapeutics-juno-shares-gap-down-on-insider-selling.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.